Mizanur Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mizanur Rahman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Gabriel Fernandes
Division of Clinical Immunology and Rheumatology, Department of Medicine University of Texas Health Science Center at San Antonio 7703 Floyd Curl Dr San Antonio TX 78229‐3900 USA
3 shared publicationsPaul J. Williams
University of Texas Health Science Center at San Antonio
3 shared publications- Gabriel Fernandes
University of Texas Health Science Center at San Antonio
2 shared publications Ganesh V. Halade
Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
2 shared publicationsArunabh Bhattacharya
1 shared publication- Arunabh Bhattacharya
Department of Cell Systems and Anatomy, The University of Texas Health Science Center, San Antonio, TX, USA; Barshop Institute for Longevity and Aging Studies, San Antonio, TX, USA
1 shared publication
Latest Publications
Conjugated Linoleic Acid Prevents Ovariectomy‐Induced Bone Loss in Mice by Modulating Both Osteoclastogenesis and Osteoblastogenesis
Postmenopausal osteoporosis due to estrogen deficiency is associated with severe morbidity and mortality. Beneficial effects of conjugated linoleic acid (CLA) on bone mineral density (BMD) have been reported in mice, rats and humans, but the effect of long term CLA supplementation against ovariectomy‐induced bone loss in mice and the mechanisms underlying this effect have not been studied yet. Eight‐week old ovariectomized (Ovx) and sham operated C57BL/6 mice were fed either a diet containing 0.5 % safflower oil (SFO) or 0.5 % CLA for 24 weeks to examine BMD, bone turn over markers and osteotropic factors. Bone marrow (BM) cells were cultured to determine the effect on inflammation, osteoclastogenesis, and osteoblastogenesis. SFO/Ovx mice had significantly lower femoral, tibial and lumbar BMD compared to SFO/Sham mice; whereas, no difference was found between CLA/Ovx and CLA/Sham mice. CLA inhibited bone resorption markers whereas enhanced bone formation markers in Ovx mice as compared to SFO‐fed mice. Reverse transcriptase polymerase chain reaction and fluorescence activated cell sorting analyses of splenocytes revealed that CLA inhibited pro‐osteoclastogenic receptor activator of NF‐κB (RANKL) and stimulated decoy receptor of RANKL, osteoprotegerin expression. CLA also inhibited pro‐inflammatory cytokine and enhanced anti‐inflammatory cytokine production of lipopolysaccharide‐stimulated splenocytes and BM cells. Furthermore, CLA inhibited osteoclast differentiation in BM and stimulated osteoblast differentiation in BM stromal cells as confirmed by tartrate resistant acid phosphatase and Alizarin Red staining, respectively. In conclusion, CLA may prevent postmenopausal bone loss not only by inhibiting excessive bone resorption due to estrogen deficiency but also by stimulating new bone formation. CLA might be a potential alternative therapy against osteoporotic bone loss.
Conjugated Linoleic Acid Prevents Ovariectomy‐Induced Bone Loss in Mice by Modulating Both Osteoclastogenesis and Osteoblastogenesis
Postmenopausal osteoporosis due to estrogen deficiency is associated with severe morbidity and mortality. Beneficial effects of conjugated linoleic acid (CLA) on bone mineral density (BMD) have been reported in mice, rats and humans, but the effect of long term CLA supplementation against ovariectomy‐induced bone loss in mice and the mechanisms underlying this effect have not been studied yet. Eight‐week old ovariectomized (Ovx) and sham operated C57BL/6 mice were fed either a diet containing 0.5 % safflower oil (SFO) or 0.5 % CLA for 24 weeks to examine BMD, bone turn over markers and osteotropic factors. Bone marrow (BM) cells were cultured to determine the effect on inflammation, osteoclastogenesis, and osteoblastogenesis. SFO/Ovx mice had significantly lower femoral, tibial and lumbar BMD compared to SFO/Sham mice; whereas, no difference was found between CLA/Ovx and CLA/Sham mice. CLA inhibited bone resorption markers whereas enhanced bone formation markers in Ovx mice as compared to SFO‐fed mice. Reverse transcriptase polymerase chain reaction and fluorescence activated cell sorting analyses of splenocytes revealed that CLA inhibited pro‐osteoclastogenic receptor activator of NF‐κB (RANKL) and stimulated decoy receptor of RANKL, osteoprotegerin expression. CLA also inhibited pro‐inflammatory cytokine and enhanced anti‐inflammatory cytokine production of lipopolysaccharide‐stimulated splenocytes and BM cells. Furthermore, CLA inhibited osteoclast differentiation in BM and stimulated osteoblast differentiation in BM stromal cells as confirmed by tartrate resistant acid phosphatase and Alizarin Red staining, respectively. In conclusion, CLA may prevent postmenopausal bone loss not only by inhibiting excessive bone resorption due to estrogen deficiency but also by stimulating new bone formation. CLA might be a potential alternative therapy against osteoporotic bone loss.
- 24 September 2013
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 141 (3) , 341-352
DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA
Breast cancer patients often develop bone metastasis evidenced by osteolytic lesions, leading to severe pain and bone fracture. Attenuation of breast cancer metastasis to bone and associated osteolysis by fish oil, rich in EPA and DHA, has been demonstrated previously. However, it was not known whether EPA and DHA differentially or similarly affect breast cancer bone metastasis and associated osteolysis. In vitro culture of parental and luciferase gene encoded MDA-MB-231 human breast cancer cell lines treated with EPA and DHA revealed that DHA inhibits proliferation and invasion of breast cancer cells more potently than EPA. Intra-cardiac injection of parental and luciferase gene encoded MDA-MB-231 cells to athymic NCr nu/nu mice demonstrated that DHA-treated mice had significantly less breast cancer cell burden in bone, and also significantly less osteolytic lesions than EPA-treated mice. In vivo cell migration assay as measured by luciferase intensity revealed that DHA attenuated cell migration specifically to the bone. Moreover, the DHA-treated group showed reduced levels of CD44 and TRAP positive area in bone compared to EPA-treated group. Breast cancer cell burden and osteolytic lesions were also examined in intra-tibially breast cancer cell injected mice and found less breast cancer cell growth and associated osteolysis in DHA-treated mice as compared to EPA-treated mice. Finally, doxorubicin-resistant MCF-7 (MCF-7dox) human breast cancer cell line was used to examine if DHA can improve sensitization of MCF-7dox cells to doxorubicin. DHA improved the inhibitory effect of doxorubicin on proliferation and invasion of MCF-7dox cells. Interestingly, drug resistance gene P-gp was also down-regulated in DHA plus doxorubicin-treated cells. In conclusion, DHA attenuates breast cancer bone metastasis and associated osteolysis more potently than EPA, possibly by inhibiting migration of breast cancer cell to the bone as well as by inhibiting osteoclastic bone resorption.
- 24 September 2013
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 141 (3) , 341-352
DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA
Breast cancer patients often develop bone metastasis evidenced by osteolytic lesions, leading to severe pain and bone fracture. Attenuation of breast cancer metastasis to bone and associated osteolysis by fish oil, rich in EPA and DHA, has been demonstrated previously. However, it was not known whether EPA and DHA differentially or similarly affect breast cancer bone metastasis and associated osteolysis. In vitro culture of parental and luciferase gene encoded MDA-MB-231 human breast cancer cell lines treated with EPA and DHA revealed that DHA inhibits proliferation and invasion of breast cancer cells more potently than EPA. Intra-cardiac injection of parental and luciferase gene encoded MDA-MB-231 cells to athymic NCr nu/nu mice demonstrated that DHA-treated mice had significantly less breast cancer cell burden in bone, and also significantly less osteolytic lesions than EPA-treated mice. In vivo cell migration assay as measured by luciferase intensity revealed that DHA attenuated cell migration specifically to the bone. Moreover, the DHA-treated group showed reduced levels of CD44 and TRAP positive area in bone compared to EPA-treated group. Breast cancer cell burden and osteolytic lesions were also examined in intra-tibially breast cancer cell injected mice and found less breast cancer cell growth and associated osteolysis in DHA-treated mice as compared to EPA-treated mice. Finally, doxorubicin-resistant MCF-7 (MCF-7dox) human breast cancer cell line was used to examine if DHA can improve sensitization of MCF-7dox cells to doxorubicin. DHA improved the inhibitory effect of doxorubicin on proliferation and invasion of MCF-7dox cells. Interestingly, drug resistance gene P-gp was also down-regulated in DHA plus doxorubicin-treated cells. In conclusion, DHA attenuates breast cancer bone metastasis and associated osteolysis more potently than EPA, possibly by inhibiting migration of breast cancer cell to the bone as well as by inhibiting osteoclastic bone resorption.
- 15 December 2011
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1240 (1) , 18-25
HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP‐β and MKP‐1
Histone deacetylases (HDACs) remove the acetyl groups from the lysine residues of histone tails, leading to the formation of a condensed and transcriptionally silenced chromatin. HDAC inhibitors (HDACi) block this action and can result in hyperacetylation of histones, leading to a less compact and more transcriptionally active chromatin and thereby, gene expression. Previously, we have shown that HDACi inhibit osteoclast differentiation. However, which genes are transcriptionally activated following hyperacetylation of histones, and lead to the suppression of osteoclastogenesis, has yet to be elucidated. In this study, we show that an HDACi, trichostatin A (TSA), inhibits the receptor activator of the nuclear factor‐κB (NF‐κB) ligand (RANKL)–stimulated TNF‐α production, NF‐κB activation, and bone resorbing pit formation, and downregulates c‐Fos and NFATc1 in RAW 264.7 cells. Interestingly, expression of antiosteoclastogenic factors CCAAT enhancer binding protein (C/EBP)‐β and mitogen‐activated protein kinase phosphatase (MKP)‐1 was significantly upregulated in TSA‐treated, RANKL‐stimulated RAW 264.7 cells. These findings suggest that TSA upregulates the expression of C/EBP‐β and MKP‐1, which may downregulate pro‐osteoclastogenic factors and signaling molecules, ultimately suppressing osteoclastogenesis.
- 15 December 2011
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1240 (1) , 18-25
HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP‐β and MKP‐1
Histone deacetylases (HDACs) remove the acetyl groups from the lysine residues of histone tails, leading to the formation of a condensed and transcriptionally silenced chromatin. HDAC inhibitors (HDACi) block this action and can result in hyperacetylation of histones, leading to a less compact and more transcriptionally active chromatin and thereby, gene expression. Previously, we have shown that HDACi inhibit osteoclast differentiation. However, which genes are transcriptionally activated following hyperacetylation of histones, and lead to the suppression of osteoclastogenesis, has yet to be elucidated. In this study, we show that an HDACi, trichostatin A (TSA), inhibits the receptor activator of the nuclear factor‐κB (NF‐κB) ligand (RANKL)–stimulated TNF‐α production, NF‐κB activation, and bone resorbing pit formation, and downregulates c‐Fos and NFATc1 in RAW 264.7 cells. Interestingly, expression of antiosteoclastogenic factors CCAAT enhancer binding protein (C/EBP)‐β and mitogen‐activated protein kinase phosphatase (MKP)‐1 was significantly upregulated in TSA‐treated, RANKL‐stimulated RAW 264.7 cells. These findings suggest that TSA upregulates the expression of C/EBP‐β and MKP‐1, which may downregulate pro‐osteoclastogenic factors and signaling molecules, ultimately suppressing osteoclastogenesis.
- 9 December 2010
- Published by Wiley in Journal of Cellular Physiology
- Vol. 226 (9) , 2406-2414
t10c12‐CLA maintains higher bone mineral density during aging by modulating osteoclastogenesis and bone marrow adiposity
Conjugated linoleic acid (CLA) has been shown to positively influence calcium and bone metabolism. Earlier, we showed that CLA (equal mixture of c9t11‐CLA and t10c12‐CLA) could protect age‐associated bone loss by modulating inflammatory markers and osteoclastogenesis. Since, c9t11‐CLA and t10c12‐CLA isomers differentially regulate functional parameters and gene expression in different cell types, we examined the efficacy of individual CLA isomers against age‐associated bone loss using 12 months old C57BL/6 female mice fed for 6 months with 10% corn oil (CO), 9.5% CO + 0.5% c9t11‐CLA, 9.5% CO + 0.5% t10c12‐CLA or 9.5% CO + 0.25% c9t11‐CLA + 0.25% t10c12‐CLA. Mice fed a t10c12‐CLA diet maintained a significantly higher bone mineral density (BMD) in femoral, tibial and lumbar regions than those fed CO and c9t11‐CLA diets as measured by dual‐energy‐X‐ray absorptiometry (DXA). The increased BMD was accompanied by a decreased production of osteoclastogenic factors, that is, RANKL, TRAP5b, TNF‐alpha and IL‐6 in serum. Moreover, a significant reduction of high fat diet‐induced bone marrow adiposity was observed in t10c12‐CLA fed mice as compared to that of CO and c9t11‐CLA fed mice, as measured by Oil‐Red‐O staining of bone marrow sections. In addition, a significant reduction of osteoclast differentiation and bone resorbing pit formation was observed in t10c12‐CLA treated RAW 264.7 cell culture stimulated with RANKL as compared to that of c9t11‐CLA and linoleic acid treated cultures. In conclusion, these findings suggest that t10c12‐CLA is the most potent CLA isomer and it exerts its anti‐osteoporotic effect by modulating osteoclastogenesis and bone marrow adiposity. J. Cell. Physiol. 226: 2406–2414, 2011.
- 9 December 2010
- Published by Wiley in Journal of Cellular Physiology
- Vol. 226 (9) , 2406-2414
t10c12‐CLA maintains higher bone mineral density during aging by modulating osteoclastogenesis and bone marrow adiposity
Conjugated linoleic acid (CLA) has been shown to positively influence calcium and bone metabolism. Earlier, we showed that CLA (equal mixture of c9t11‐CLA and t10c12‐CLA) could protect age‐associated bone loss by modulating inflammatory markers and osteoclastogenesis. Since, c9t11‐CLA and t10c12‐CLA isomers differentially regulate functional parameters and gene expression in different cell types, we examined the efficacy of individual CLA isomers against age‐associated bone loss using 12 months old C57BL/6 female mice fed for 6 months with 10% corn oil (CO), 9.5% CO + 0.5% c9t11‐CLA, 9.5% CO + 0.5% t10c12‐CLA or 9.5% CO + 0.25% c9t11‐CLA + 0.25% t10c12‐CLA. Mice fed a t10c12‐CLA diet maintained a significantly higher bone mineral density (BMD) in femoral, tibial and lumbar regions than those fed CO and c9t11‐CLA diets as measured by dual‐energy‐X‐ray absorptiometry (DXA). The increased BMD was accompanied by a decreased production of osteoclastogenic factors, that is, RANKL, TRAP5b, TNF‐alpha and IL‐6 in serum. Moreover, a significant reduction of high fat diet‐induced bone marrow adiposity was observed in t10c12‐CLA fed mice as compared to that of CO and c9t11‐CLA fed mice, as measured by Oil‐Red‐O staining of bone marrow sections. In addition, a significant reduction of osteoclast differentiation and bone resorbing pit formation was observed in t10c12‐CLA treated RAW 264.7 cell culture stimulated with RANKL as compared to that of c9t11‐CLA and linoleic acid treated cultures. In conclusion, these findings suggest that t10c12‐CLA is the most potent CLA isomer and it exerts its anti‐osteoporotic effect by modulating osteoclastogenesis and bone marrow adiposity. J. Cell. Physiol. 226: 2406–2414, 2011.
- Open Access
- 1 January 2009
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2 (5) , 307-316
The Fat-1 Transgene in Mice Increases Antioxidant Potential, Reduces Pro‐Inflammatory Cytokine Levels, and Enhances PPARγ and SIRT‐1 Expression on a Calorie Restricted Diet
Both n‐3 fatty acids (FA) and calorie‐restriction (CR) are known to exert anti‐inflammatory and anti‐oxidative effects in animals and humans. In this study, we investigated the synergistic anti‐inflammatory and anti‐oxidative capacity of n‐3 FA and CR using Fat‐1 transgenic mice (Fat‐1) that are capable of converting n‐6 FA to n‐3 FA endogenously. Wild type (WT) and Fat‐1 mice were maintained on ad libitum (AL) or CR (40% less than AL) AIN‐93 diet supplemented with 10% corn oil (rich in n‐6 FA) for 5 months. Significantly lower levels of n‐6/n‐3 FA ratio were observed in serum, muscle and liver of Fat‐1 mice fed AL or CR as compared to that of WT mice fed AL or CR. Muscle catalase (CAT), super oxide dismutase (SOD), glutathione peroxidase (GPX) activities, and liver CAT and SOD activities were found higher in Fat‐1 mice as compared to that of WT mice. These activities were more pronounced in Fat‐1/CR group as compared to other groups. Serum pro‐inflammatory markers, such as tumor necrosis factor (TNF)α, interleukin (IL)‐1β and IL‐6 were found lower in Fat‐1 mice, as compared to that of WT mice. This anti‐inflammatory effect was also more pronounced in Fat‐1/CR group as compared to that of other groups. Furthermore, significantly higher levels of peroxisome proliferator‐activated receptor (PPA R)gamma and life prolonging gene, sirtuin (SIRT)‐1 expression were found in liver of Fat‐1/CR mice, as compared to that of WT/CR mice. These data suggest that n‐3 FA along with moderate CR may prolong lifespan by attenuating inflammation and oxidative stress.
- 1 January 2009
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2 (5) , 307-316
Open AccessThe Fat-1 Transgene in Mice Increases Antioxidant Potential, Reduces Pro‐Inflammatory Cytokine Levels, and Enhances PPARγ and SIRT‐1 Expression on a Calorie Restricted Diet
Both n‐3 fatty acids (FA) and calorie‐restriction (CR) are known to exert anti‐inflammatory and anti‐oxidative effects in animals and humans. In this study, we investigated the synergistic anti‐inflammatory and anti‐oxidative capacity of n‐3 FA and CR using Fat‐1 transgenic mice (Fat‐1) that are capable of converting n‐6 FA to n‐3 FA endogenously. Wild type (WT) and Fat‐1 mice were maintained on ad libitum (AL) or CR (40% less than AL) AIN‐93 diet supplemented with 10% corn oil (rich in n‐6 FA) for 5 months. Significantly lower levels of n‐6/n‐3 FA ratio were observed in serum, muscle and liver of Fat‐1 mice fed AL or CR as compared to that of WT mice fed AL or CR. Muscle catalase (CAT), super oxide dismutase (SOD), glutathione peroxidase (GPX) activities, and liver CAT and SOD activities were found higher in Fat‐1 mice as compared to that of WT mice. These activities were more pronounced in Fat‐1/CR group as compared to other groups. Serum pro‐inflammatory markers, such as tumor necrosis factor (TNF)α, interleukin (IL)‐1β and IL‐6 were found lower in Fat‐1 mice, as compared to that of WT mice. This anti‐inflammatory effect was also more pronounced in Fat‐1/CR group as compared to that of other groups. Furthermore, significantly higher levels of peroxisome proliferator‐activated receptor (PPA R)gamma and life prolonging gene, sirtuin (SIRT)‐1 expression were found in liver of Fat‐1/CR mice, as compared to that of WT/CR mice. These data suggest that n‐3 FA along with moderate CR may prolong lifespan by attenuating inflammation and oxidative stress.
- Open Access
- 1 January 2006
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 5 (1) , 7
Effects of conjugated linoleic acid and exercise on bone mass in young male Balb/C mice
There is an increase in obesity among the population of industrialized countries, and dietary supplementation with Conjugated Linoleic Acid (CLA) has been reported to lower body fat mass. However, weight loss is generally associated with negative effects on bone mass, but CLA is reported to have beneficial effects on bone. Furthermore, another factor that is well established to have a beneficial effect on bone is exercise (EX). However, a combination therapy of CLA and EX on bone health has not been studied. In this paper, we report the beneficial effects of CLA and EX on bone, in four different groups of Balb-C young, male mice. There were 4 groups in our study: 1. Safflower oil (SFO) sedentary (SED); 2. SFO EX; 3. CLA SED; 4. CLA EX. Two months old mice, under their respective treatment regimens were followed for 14 weeks. Mice were scanned in vivo using a DEXA scanner before and after treatment. At the end of the treatment period, the animals were sacrificed, the left tibia was removed and scanned using peripheral quantitative computerized tomography (pQCT). The results showed that although CLA decreased gain in body weight by 35%, it however increased bone mass by both reducing bone resorption and increasing bone formation. EX also decreased gain in body weight by 21% and increased bone mass; but a combination of CLA and EX, however, did not show any further increase in bone mass. In conclusion, CLA increases bone mass in both cancellous and cortical bones, and the effects of CLA on bone is not further improved by EX in pure cortical bone of young male mice.
- 1 January 2006
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 5 (1) , 7
Open AccessEffects of conjugated linoleic acid and exercise on bone mass in young male Balb/C mice
There is an increase in obesity among the population of industrialized countries, and dietary supplementation with Conjugated Linoleic Acid (CLA) has been reported to lower body fat mass. However, weight loss is generally associated with negative effects on bone mass, but CLA is reported to have beneficial effects on bone. Furthermore, another factor that is well established to have a beneficial effect on bone is exercise (EX). However, a combination therapy of CLA and EX on bone health has not been studied. In this paper, we report the beneficial effects of CLA and EX on bone, in four different groups of Balb-C young, male mice. There were 4 groups in our study: 1. Safflower oil (SFO) sedentary (SED); 2. SFO EX; 3. CLA SED; 4. CLA EX. Two months old mice, under their respective treatment regimens were followed for 14 weeks. Mice were scanned in vivo using a DEXA scanner before and after treatment. At the end of the treatment period, the animals were sacrificed, the left tibia was removed and scanned using peripheral quantitative computerized tomography (pQCT). The results showed that although CLA decreased gain in body weight by 35%, it however increased bone mass by both reducing bone resorption and increasing bone formation. EX also decreased gain in body weight by 21% and increased bone mass; but a combination of CLA and EX, however, did not show any further increase in bone mass. In conclusion, CLA increases bone mass in both cancellous and cortical bones, and the effects of CLA on bone is not further improved by EX in pure cortical bone of young male mice.